[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645432":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":7,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"IRCCS San Raffaele","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Giulio Ferrari, MD, PhD, Professor","CONTACT","+390226436186","ferrari.giulio@hsr.it",[15],{"facility":16,"status":7,"city":17,"state":7,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"IRCCS San Raffaele Scientific Institute","Milan","20132","Italy","IT",{"type":22,"coordinates":23},"Point",[24,25],12.59836,42.78235,{"lat":25,"lon":24},[28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Giulio Ferrari","Professor","100645432","clinical-predictors-of-visual-outcome-in-patients-affected-with-ocular-surface-diseases-100645432",false,"NCT07694817","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases","Clinical Predictors of Visual Outcome in Patients Affected With Ocular Surface Diseases: Single Center Retrospective-prospective Clinical Study","OSD","Inclusion Criteria:\n\n* The participant is willing and able to provide written informed consent for study participation (prospective cohort).\n* Adult participants aged ≥18 years at the time of inclusion.\n* Clinically confirmed diagnosis of OSD, including but not limited to inflammatory keratopathies, neurotrophic keratopathy, exposure keratopathy, limbal stem cell deficiency, post-surgical or post-traumatic corneal alterations.\n* Measurable BSCVA obtained through standardized manifest refraction and ETDRS chart testing at baseline.\n* Available dataset for the diagnostic tests required by the study (e.g., corneal topography, pachymetry, confocal microscopy, corneal sensitivity testing, slit-lamp imaging, tear cytokine analysis, impression cytology).\n* Willingness and ability to attend follow-up visits and complete all study-related procedures according to the study schedule.\n\nExclusion Criteria:\n\n* Change of retinal, optic nerve, or macular pathology that may affect best spectacle-corrected visual acuity independently of the cornea or ocular surface (e.g., age-related macular degeneration, diabetic macular edema, optic neuropathy) in the period of study\n* History of intraocular or corneal surgery within 3 months prior to baseline evaluation.\n* Active intraocular inflammation, glaucoma with uncontrolled intraocular pressure, or corneal conditions not compatible with accurate imaging or measurement (e.g., severe scarring, leukoma).\n* Uncontrolled systemic diseases that may impair vision or corneal health (e.g., advanced diabetes, autoimmune disease in active phase).\n* Inability or unwillingness to attend follow-up visits or complete study assessments.\n* Pregnant or breastfeeding women will not be enrolled, as hormonal fluctuations can alter tear film and ocular surface physiology","ALL",{"count":43,"type":44},1000,"ESTIMATED","OBSERVATIONAL","This retrospective-prospective study aims to identify the diagnostic parameters most predictive of BSCVA in patients with OSD. Clinical, structural, and biochemical data will be collected from standard-of-care examinations and patient-reported outcome questionnaires. The goal is to determine the most informative biomarkers for visual prognosis, streamline diagnostic workflows, and support individualized management of OSD.",[48,49,50,51,52,53],"Neurotrophic Keratopathy","Exposure Keratopathy","Limbal Stem Cell Deficiency (LSCD)","Cornea Abnormality","Cornea Disease","Cornea Inflamed","NOT_YET_RECRUITING","2026-07-10",{"date":57,"type":58},"2026-07-14","ACTUAL",{"date":60,"type":44},"2026-07",{"date":62,"type":44},"2029-12",{"name":5,"class":6},1]